Previous literature shows that TB patients with a slow acetylator phenotype of N-acetyltransferase 2, compared to the rapid acetylator phenotype of N-acetyltransferase 2, have a higher risk of anti-TB drug-induced hepatotoxicity. The gene discussed is NAT2; the disease is tuberculosis.